A5069496306- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Atrial Fibrillation Management and Outcomes
- Cardiac electrophysiology and arrhythmias
- Erythropoietin and Anemia Treatment
- Cardiac Arrhythmias and Treatments
- Blood Pressure and Hypertension Studies
- Cardiac Imaging and Diagnostics
- Hormonal Regulation and Hypertension
- Iron Metabolism and Disorders
- Potassium and Related Disorders
- Cardiac Structural Anomalies and Repair
- Cardiovascular Issues in Pregnancy
- Heart Rate Variability and Autonomic Control
- Cardiovascular and exercise physiology
- Dialysis and Renal Disease Management
- Cardiac Health and Mental Health
- Congenital Heart Disease Studies
- Galectins and Cancer Biology
- Pulmonary Hypertension Research and Treatments
- Acute Kidney Injury Research
- Heart rate and cardiovascular health
- Acute Myocardial Infarction Research
- Peptidase Inhibition and Analysis
University Medical Center Groningen
2016-2025
University of Groningen
2016-2025
British Heart Foundation
2013-2023
Nagoya University
2023
Harbin Medical University
2012-2023
Second Affiliated Hospital of Harbin Medical University
2023
Brandenburg University of Technology Cottbus-Senftenberg
2023
University of Toronto
2023
Tzu Chi University
2023
Uppsala University
2015-2020
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and after myocardial infarction. We evaluated the effects of eplerenone in chronic mild symptoms.
The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with and ejection fraction. effect inhibition in preserved fraction is unclear.
Aims Large randomized trials have shown that beta-blockers reduce mortality and hospital admissions in patients with heart failure. The effects of elderly a broad range left ventricular ejection fraction are uncertain. SENIORS study was performed to assess the beta-blocker, nebivolol, ≥70 years, regardless fraction.
For the general population, clinical relevance of an increased urinary albumin excretion rate is still debated. Therefore, we examined relationship between and all-cause mortality caused by cardiovascular (CV) disease non-CV in population.In period 1997 to 1998, all inhabitants city Groningen, Netherlands, aged 28 75 years (n=85 421) were sent a postal questionnaire collecting information about risk factors for CV morbidity vial collect early morning urine sample measurement concentration...
Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins theoretical risks these patients.A total of 5011 patients at least 60 years age New York Heart Association class II, III, or IV ischemic, were randomly assigned to receive 10 mg rosuvastatin placebo per day. The primary composite outcome was death cardiovascular causes, nonfatal myocardial infarction, stroke. Secondary outcomes included any...
The aim of this study was to evaluate the benefits and safety long-term i.v. iron therapy in iron-deficient patients with heart failure (HF). CONFIRM-HF a multi-centre, double-blind, placebo-controlled trial that enrolled 304 ambulatory symptomatic HF left ventricular ejection fraction ≤45%, elevated natriuretic peptides, deficiency (ferritin <100 ng/mL or 100–300 if transferrin saturation <20%). Patients were randomized 1 : treatment iron, as ferric carboxymaltose (FCM, n = 152) placebo...
Background —Because renal function is affected by chronic heart failure (CHF) and it relates to both cardiovascular hemodynamic properties, should have additional prognostic value. We studied whether a predictor for mortality in advanced CHF, we assessed its relative contribution compared with other established risk factors. In addition, the relation between neurohormonal activation. Methods Results —The study population consisted of 1906 patients CHF who were enrolled recent survival trial...
Rate control is often the therapy of choice for atrial fibrillation. Guidelines recommend strict rate control, but this not based on clinical evidence. We hypothesized that lenient inferior to preventing cardiovascular morbidity and mortality in patients with permanent fibrillation.We randomly assigned 614 fibrillation undergo a rate-control strategy (resting heart <110 beats per minute) or <80 minute during moderate exercise minute). The primary outcome was composite death from causes,...
Background— Decreased renal function has been found to be an independent risk factor for cardiovascular outcomes in patients with chronic heart failure (CHF) markedly reduced left ventricular ejection fraction (LVEF). The aim of this analysis was evaluate the prognostic importance a broader spectrum CHF. Methods and Results— Candesartan Heart Failure:Assessment Reduction Mortality Morbidity (CHARM) program consisted three component trials that enrolled symptomatic CHF, based on use ACE...
Iron deficiency (ID) is an emerging problem in patients with chronic heart failure (HF) and can be a potential therapeutic target. However, not much known about the prevalence, predictors, prognosis of ID HF. In international pooled cohort comprising 1,506 HF, we studied clinical associates its prognostic consequences. (defined as ferritin level <100 μg/L or 100-299 transferrin saturation <20%) was present 753 (50%). Anemic were more often iron deficient than nonanemic (61.2% vs 45.6%, P <...
Methods and resultsIn 1802 women with CHD, 1302 completed pregnancies were observed. Independent predictors of cardiac, obstetric, neonatal complications calculated using logistic regression. The most prevalent cardiac during pregnancy arrhythmias (4.7%) heart failure (1.6%). Factors independently associated maternal the presence cyanotic disease (corrected/uncorrected) (P < 0.0001), use medication before left obstruction 0.0001). New characteristics mechanical valve replacement = 0.0014),...
One large study, MIRACLE ICD 9 and one meta-analysis 15 support the choice of a CRT-D in patients NYHA class III/IV, with LVEF ≤35%, QRS width ≥120 ms conventional indication for an ICD.Key points † New: LV dilatation no longer required recommendation.† IV should be ambulatory.† reasonable expectation survival good functional status .1 year CRT-D.† Evidence is strongest typical LBBB.† Similar level evidence CRT-P CRT-D.